Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.

ABSTRACT:

Purpose

HLA-mismatched unrelated donor (MMUD) hematopoietic stem-cell transplantation (HSCT) is associated with increased graft-versus-host disease (GVHD) and impaired survival. In reduced-intensity conditioning (RIC), neither ex vivo nor in vivo T-cell depletion (eg, antithymocyte globulin) convincingly improved outcomes. The proteasome inhibitor bortezomib has immunomodulatory properties potentially beneficial for control of GVHD in T-cell-replete HLA-mismatched transplantation.

Patients and methods

We conducted a prospective phase I/II trial of a GVHD prophylaxis regimen of short-course bortezomib, administered once per day on days +1, +4, and +7 after peripheral blood stem-cell infusion plus standard tacrolimus and methotrexate in patients with hematologic malignancies u

SUBMITTER: Koreth J 

PROVIDER: S-EPMC3434979 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature